For HCPs Only
Recent Clinical Updates
Loading latest clinical updates

Clinical Intelligence & Drug Records for US-Licensed Practitioners

The integrated, institutional-grade registry trusted by US-licensed practitioners for evidence-based clinical data, drug information, and peer-reviewed clinical updates.

Clinical Update Briefing

Weekly drug approvals, safety updates, and specialty coverage for healthcare professionals.

Clinical Resources

Drug updates, reference data, and specialist-led coverage.

Recent Clinical Updates

Latest Drug & Specialty Updates

View All

Specialty Coverage

Therapeutic-area updates for clinical review.

All Specialties

Drug Information

FDA drug records and prescribing context.

Review drug records, NDC references, dosage tools, and interaction resources alongside clinical coverage.

Clinical Coverage

Additional Clinical Updates

Pharmacology

EXPLORER-HCM: Mavacamten Achieved 37% Versus 17% Primary Endpoint in Obstructive HCM

Jul 24|5 min read|By Editorial Team
Oncology

FDA Approves relacorilant for Platinum-Resistant Ovarian Cancer; PFS HR 0.70 (ROSELLA)

Jul 24|6 min read|By Dr. Meera Pillai
Neurology

Oveporexton: Increases Wakefulness (MWT) 25.4 min in Narcolepsy Type 1

Jul 23|5 min read|By Dr. Aditi Kulkarni
Neurology

FDA Approves Leucovorin for Cerebral Folate Transport Deficiency

Jul 23|5 min read|By Dr. Aditi Kulkarni
Hematology

AURORA: Bitopertin Reduced Protoporphyrin‑IX 49.8% in Erythropoietic Protoporphyria

Jul 22|5 min read|By Dr. Shruti Pandey
Rare Disease

FDA Approves Elamipretide for Barth Syndrome: 63 N Knee Strength Gain

Jul 22|5 min read|By Editorial Team
Otolaryngology

FDA Approves lunsotogene parvec for OTOF Hearing Loss: 80% ≤70 dB PTA

Jul 22|6 min read|By Editorial Team
Rare Disease

FDA Approves KYGEVVI for TK2d: Cuts Death Risk 86%

Jul 22|6 min read|By Editorial Team
Oncology

FDA Approves vepdegestrant for ESR1‑Mutated ER+ HER2‑ Breast Cancer; PFS HR 0.58 in VERITAC‑2

Jul 21|5 min read|By Dr. Rahul Verma
Neurology

lecanemab and donanemab: amyloid confirmation and PET criteria for patient selection

Jul 20|5 min read|By Dr. Vikram Patel
Oncology

Bispecific Antibodies in Oncology: Mechanisms and Approved Indications

Jul 20|11 min read|By Dr. Meera Pillai
Neurology

FDA Approves ofatumumab for Relapsing MS: Cuts Relapse Rate 51%

Jul 20|5 min read|By Dr. Vikram Patel
Pulmonology

Mepolizumab: Severe Asthma Rate Ratio 0.47 (MENSA)

Jul 20|6 min read|By Dr. Nikhil Chatterjee
Infectious Disease

REVIVE: Fluvoxamine Reduces Fatigue Severity (−0.43 FSS) vs Placebo

Jul 20|5 min read|By Dr. Simran Kohli
Neurology

FDA Approves Copper Histidinate for Menkes: Cuts Death Risk 78%

Jul 19|6 min read|By Dr. Vikram Patel
Hematology

narsoplimab: FDA Approves for TA-TMA; 61% TMA Response

Jul 19|5 min read|By Dr. Shruti Pandey
Oncology

FDA Approves datopotamab deruxtecan for EGFR‑mutant NSCLC: 45% ORR

Jul 19|6 min read|By Dr. Meera Pillai
Cardiology

enlicitide Cuts LDL-C 56% and 59% in Phase 3 CORALreef Trials

Jul 19|5 min read|By Dr. Kavya Sharma
Cardiology

Evolocumab Cuts LDL 63%; Alirocumab and Inclisiran: Data Guide

Jul 19|6 min read|By Dr. Kavya Sharma
Neurology

FDA Approves Atogepant for Episodic Migraine: 1.7‑Day MMD Drop (ADVANCE)

Jul 18|6 min read|By Dr. Vikram Patel
Oncology

FDA Approves Olaparib for HRR‑mutated mCRPC: HR 0.34 PFS (PROfound)

Jul 18|6 min read|By Dr. Rahul Verma
Infectious Disease

Nirmatrelvir/Ritonavir Cuts Hospitalization Risk 89% in EPIC-HR

Jul 18|6 min read|By Dr. Simran Kohli
Oncology

FDA Approves Mirdametinib for NF1 PN: 41% ORR in Adults (ReNeu)

Jul 18|5 min read|By Dr. Meera Pillai